|
gptkbp:instanceOf
|
gptkb:receptor_tyrosine_kinase
gptkb:drug
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2002
|
|
gptkbp:ATCCode
|
L01XE02
|
|
gptkbp:bioavailability
|
~60%
|
|
gptkbp:brand
|
gptkb:Iressa
|
|
gptkbp:CASNumber
|
184475-35-2
|
|
gptkbp:contraindication
|
hypersensitivity to gefitinib
|
|
gptkbp:developedBy
|
gptkb:AstraZeneca
|
|
gptkbp:discoveredBy
|
gptkb:AstraZeneca
|
|
gptkbp:eliminationHalfLife
|
41 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:genericName
|
gptkb:gefitinib
|
|
gptkbp:hasInChIKey
|
YFSZZTSWQAGQDF-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C22H24ClFN4O3
|
|
gptkbp:hasSMILES
|
COC1=CC2=C(C=C1)N=C(NC3=CC=CC=C3F)N=C2OCCN4CCOCC4.Cl
|
|
gptkbp:hasUNII
|
S2A4ZGM9G8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
gefitinib
|
|
gptkbp:indication
|
gptkb:EGFR_mutation-positive_non-small_cell_lung_cancer
|
|
gptkbp:KEGGID
|
D00554
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits EGFR tyrosine kinase
|
|
gptkbp:MeSH_ID
|
C477489
|
|
gptkbp:metabolism
|
gptkb:CYP2D6
gptkb:CYP3A4
|
|
gptkbp:molecularWeight
|
446.9 g/mol
|
|
gptkbp:patent
|
gptkb:AstraZeneca
|
|
gptkbp:pregnancyCategory
|
gptkb:D_(Australia)
Not assigned (US)
|
|
gptkbp:proteinBinding
|
90%
|
|
gptkbp:PubChem_CID
|
110019
123631
CHEBI:49668
DB00317
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
anorexia
rash
interstitial lung disease
|
|
gptkbp:synonym
|
gptkb:ZD1839
|
|
gptkbp:target
|
gptkb:epidermal_growth_factor_receptor
|
|
gptkbp:usedFor
|
gptkb:non-small_cell_lung_cancer
|
|
gptkbp:bfsParent
|
gptkb:EGFR
gptkb:EGFR_gene
gptkb:P15056
gptkb:P42338
gptkb:CYP3A5
gptkb:EGFR_signaling_pathway
gptkb:CYP3A4_gene
|
|
gptkbp:bfsLayer
|
6
|